Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ARRY 3.70 +0.01 (0.27%)
price chart
History of Array BioPharma Inc. (NASDAQ:ARRY) stock price after earnings
Array BioPharma Inc. (NASDAQ:ARRY) is expected to announce fourth quarter financial results estimated on August 08, 2016. The company added about 9.4 percent in value since last earnings when it was at $3.31.
Array BioPharma Inc. (NASDAQ:ARRY) Upcoming Earnings: What matter for investors?  The Voice Registrar
Array BioPharma (ARRY) Shares are Down -2.16%  Trade Calls
3M Company (NYSE:MMM) Went Down -0.45%: Array BioPharma Inc. (NASDAQ:ARRY ...
3M Company (NYSE:MMM) traded 1.93 Million shares on last trading day with closing price of $179.63. Company gross margin stands at 49.50% whereas its return on investment (ROI) is 22.00%.
Here's Why Array Biopharma Inc. Gained 18.1% in May
What: Investors in Array BioPharma (NASDAQ:ARRY), a clinical-stage biotechnology company focused on cancer, had a prosperous May.
All You Need To Know About Array Biopharma Inc's (NASDAQ:ARRY) Upcoming NDA ...
Array Biopharma Inc (NASDAQ:ARRY) just reported detailed topline from a recently completed oncology pivotal, and alongside the report, announced it expects to submit a New Drug Application (NDA) to the FDA before the end of this month.
Array Biopharma Inc (NASDAQ:ARRY) Given $8.14 Consensus Target Price by Analysts  The Point Review
Array Biopharma Inc (ARRY) Stock Rating Reaffirmed by Cantor Fitzgerald  The Cerbat Gem
Focus on Analyst Targeted Prices: Cara Therapeutics, Inc. (NASDAQ:CARA ...
Cara Therapeutics, Inc. (NASDAQ:CARA) negotiated 4.95 million shares against it an average volume of 682.1 thousand shares.
Is it Finally Safe to Buy Array BioPharma Inc (NASDAQ:ARRY)?
[EDGAR] Array BioPharma Inc (NASDAQ:ARRY)(TREND ANALYSIS) issued two press releases announcing additional data from a Phase 2 study of encorafenib-based regimens in patients with BRAF-mutant colorectal cancer and initiation of a Phase 3 trial ...
Array Biopharma Inc Stock Gains on Phase 3 BEACON CRC Trial Commencement  Bidness ETC
Home Earnings Array BioPharma Inc. | $ARRY Stock | Shares Spike Up On ...
Array BioPharma Inc. (ARRY), a biopharmaceutical company yesterday announced that they are submitting for new drug application of their drug binimetinib.
Biotech Stocks Worth Chasing: Array BioPharma Inc. (ARRY), XOMA Corporation ...  Zergwatch
Why Array Is Making a Run  24/7 Wall St.
Array BioPharma Inc. Stock Momentum at Critical Inflection Point
This is a momentum stock rating analysis for Array BioPharma Inc. (NASDAQ:ARRY) . The company has a three bull momentum rating which indicates an inflection point.
Array BioPharma (ARRY) : Analyst Rating Update  Trade Calls
Array Biopharma Inc (NASDAQ:ARRY) Analyst Opinion
Array Biopharma Inc (NASDAQ:ARRY) stock is currently trading at about $3.63 and lots of rating firms seem to have a target price set on the stock.
Array BioPharma Inc. (NASDAQ:ARRY) Has $0.005 In Comprehensive Income  Enterprise Leader
Array BioPharma Inc. (NASDAQ:ARRY) Moved up 1.97%: Bank of Commerce Holdings ...  Benchmark Monitor
Two Biotechnology Names Are Hot: Array BioPharma Inc. (ARRY), EPIRUS ...
Array BioPharma Inc. (ARRY) ended last trading session with a change of -2.65 percent. It trades at an average volume of 1.96M shares versus 1.2M shares recorded at the end of last trading session.